Who owns ARS Pharmaceuticals, Inc. (ALTUQ)? Elite investor 13F holders
3 tracked elite investors reported holding ARS Pharmaceuticals, Inc as of 2026-06-30, including Rubric Capital, Third Point, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | Ars Pharmaceuticals Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 68412297.00 USD | 8540861.000000 | Shares | add | Original filing |
| Third Point | Ars Pharmaceuticals Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 8010000.00 USD | 1000000.000000 | Shares | hold | Original filing |
| Tudor Investment | Ars Pharmaceuticals Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 367619.00 USD | 45895.000000 | Shares | buy | Original filing |
| D.E. Shaw | Ars Pharmaceuticals Inc | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.